drugset / Trial / NCT05743244
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Phase 2
Active not recruiting
78 enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Pfizer · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Timeline
- Start
- 2023-10-19
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abrocitinib | Small molecule | 200 mg | Oral |
| Subject | Ritlecitinib | Small molecule | 100 mg | Oral |